Vaginal progesterone to reduce preterm birth among HIV-infected pregnant women in Zambia: a feasibility study protocol
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2055-5784
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Vaginal progesterone to reduce preterm birth among HIV-infected pregnant women in Zambia: a feasibility study protocol ; volume:4 ; number:1 ; day:18 ; month:7 ; year:2017 ; pages:1-9 ; date:12.2018
Pilot and feasibility studies ; 4, Heft 1 (18.7.2017), 1-9, 12.2018
- Schlagwort
-
Iatrogene Krankheit
Therapie
Compliance
- Urheber
-
Price, Joan T.
- Beteiligte Personen und Organisationen
-
Mollan, Katie R.
Fuseini, Nurain M.
Freeman, Bethany L.
Mulenga, Helen B.
Corbett, Amanda H.
Vwalika, Bellington
Stringer, Jeffrey S. A.
SpringerLink (Online service)
- DOI
-
10.1186/s40814-017-0170-7
- URN
-
urn:nbn:de:1111-201708215874
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:39 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Price, Joan T.
- Mollan, Katie R.
- Fuseini, Nurain M.
- Freeman, Bethany L.
- Mulenga, Helen B.
- Corbett, Amanda H.
- Vwalika, Bellington
- Stringer, Jeffrey S. A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
The interaction between vaginal microbiota, cervical length, and vaginal progesterone treatment for preterm birth risk
The vaginal microbiome and preterm birth
Patients’ administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support
Placental progesterone and its receptor in HIV-infected pre-eclamptic women
Vaginal progesterone for the prevention of preterm birth: who can benefit and who cannot? Evidence-based recommendations for clinical use
Prevention of Preterm Birth by Cervical Pessary Combined with Vaginal Progesterone: a Systematic Review and Meta-analysis with Trial Sequential Analysis
Rescue Adjuvant Vaginal Progesterone May Improve Outcomes in Cervical Cerclage Failure
Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial
The vaginal microbial signatures of preterm birth woman
Clinical Application of Progesterone for the Prevention of Preterm Birth, 2016
Addressing Decision Making in Progesterone Treatment for History of Preterm Delivery
Thermosensitive Progesterone Hydrogel: A Safe and Effective New Formulation for Vaginal Application
The interaction between vaginal microbiota, cervical length, and vaginal progesterone treatment for preterm birth risk
The vaginal microbiome and preterm birth
Patients’ administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support
Placental progesterone and its receptor in HIV-infected pre-eclamptic women
Vaginal progesterone for the prevention of preterm birth: who can benefit and who cannot? Evidence-based recommendations for clinical use
Prevention of Preterm Birth by Cervical Pessary Combined with Vaginal Progesterone: a Systematic Review and Meta-analysis with Trial Sequential Analysis
Rescue Adjuvant Vaginal Progesterone May Improve Outcomes in Cervical Cerclage Failure
Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial
The vaginal microbial signatures of preterm birth woman
Clinical Application of Progesterone for the Prevention of Preterm Birth, 2016
Addressing Decision Making in Progesterone Treatment for History of Preterm Delivery
Thermosensitive Progesterone Hydrogel: A Safe and Effective New Formulation for Vaginal Application
The interaction between vaginal microbiota, cervical length, and vaginal progesterone treatment for preterm birth risk
The vaginal microbiome and preterm birth
Patients’ administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support
Placental progesterone and its receptor in HIV-infected pre-eclamptic women
Vaginal progesterone for the prevention of preterm birth: who can benefit and who cannot? Evidence-based recommendations for clinical use
Prevention of Preterm Birth by Cervical Pessary Combined with Vaginal Progesterone: a Systematic Review and Meta-analysis with Trial Sequential Analysis
Rescue Adjuvant Vaginal Progesterone May Improve Outcomes in Cervical Cerclage Failure
Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial
The vaginal microbial signatures of preterm birth woman
Clinical Application of Progesterone for the Prevention of Preterm Birth, 2016
Addressing Decision Making in Progesterone Treatment for History of Preterm Delivery